cysteine rich protein 1 pseudogene 4Genealiases: []
Q-omics provides the consensus-scored CRIP1P4 profile across patient tissues and cancer cell-line models. CRIP1P4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CRIP1P4 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, CRIP1P4 RNA expression shows 7,500 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight ACC, BRCA, and READ as cancer lineages where CRIP1P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRIP1P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRIP1P4 survival associations across molecular data types. CRIP1P4 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRIP1P4 RNA expression–survival associations across cancer types. High CRIP1P4 expression shows unfavorable associations in ACC, LAML, PCPG, READ and PAAD, but favorable associations in BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify ACC as the clearest survival context for CRIP1P4 RNA expression.
This table summarizes CRIP1P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CRIP1P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRIP1P4 shows lower tumor expression in LUSC and THCA and higher tumor expression in BRCA, KIRC, STAD and UCEC. The BRCA box plot shows higher CRIP1P4 RNA expression in tumor versus normal tissue (log2 FC = +0.271, t-test p < 0.001).
This table shows molecular features associated with CRIP1P4 in patient tissues and cancer cell lines. In patient samples, CRIP1P4 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set.
